Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 3/306% below fair value
$7.98−0.25 (-3.04%)
Close on Nov 19, 2026Market cap $232.42MP/E –Yield –
Enanta Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Enanta Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was -$42.77M. For fiscal 2026 it was -$42.77M. The highest annual figure on record is $74.34M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | -$42.77M | – |
| FY2025 | Sep 30, 2025 | -$32.17M | – |
| FY2024 | Sep 30, 2024 | -$96.71M | – |
| FY2023 | Sep 30, 2023 | -$112.21M | – |
| FY2022 | Sep 30, 2022 | -$86.91M | – |
| FY2021 | Sep 30, 2021 | -$70.75M | -1353.7% |
| FY2020 | Sep 30, 2020 | $5.64M | -91.5% |
| FY2019 | Sep 30, 2019 | $66.00M | +151.5% |
| FY2018 | Sep 30, 2018 | $26.24M | -47.7% |
| FY2017 | Sep 30, 2017 | $50.15M | +61.4% |
| FY2016 | Sep 30, 2016 | $31.07M | -58.2% |
| FY2015 | Sep 30, 2015 | $74.34M | +288.2% |
| FY2014 | Sep 30, 2014 | $19.15M | +90.6% |
| FY2013 | Sep 30, 2013 | $10.05M | -55.1% |
| FY2012 | Sep 30, 2012 | $22.37M | -5.1% |
| FY2011 | Sep 30, 2011 | $23.57M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | -$13.77M | – |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$9.98M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$7.17M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$11.84M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$7.95M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$25.55M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$19.35M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$21.32M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$30.27M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$25.78M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$22.97M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$34.28M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$16.17M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$38.80M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$16.97M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$29.85M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$26.45M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$13.63M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$21.05M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$29.91M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$4.71M | -132.9% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$15.08M | -227.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$15.79M | -291.4% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$4.76M | -1671.3% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $14.32M | -48.1% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $11.88M | -60.2% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $8.25M | -70.2% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $303.00K | -89.7% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $27.58M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $29.87M | +664.9% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $27.72M | -51.4% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $2.95M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$8.33M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $3.91M | +78.1% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $57.07M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$5.54M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$3.58M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $2.19M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$2.54M | – |
See a number that looks wrong?